Teva Pharmaceutical Industries Ltd to Post FY2019 Earnings of $2.18 Per Share, Gabelli Forecasts (TEVA)

Share on StockTwits

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Equities research analysts at Gabelli dropped their FY2019 earnings per share estimates for shares of Teva Pharmaceutical Industries in a research note issued on Monday, May 6th. Gabelli analyst K. Kedra now forecasts that the company will post earnings of $2.18 per share for the year, down from their previous forecast of $2.23.

A number of other analysts have also recently commented on TEVA. Zacks Investment Research cut shares of Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Monday, January 21st. UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating in a report on Wednesday, January 23rd. Piper Jaffray Companies raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and upped their target price for the company from $15.00 to $16.00 in a report on Wednesday, January 23rd. Bank of America reaffirmed a “buy” rating and set a $24.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 5th. Finally, HSBC set a $12.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “sell” rating in a report on Tuesday, February 5th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average target price of $20.58.

Shares of TEVA stock opened at $14.60 on Wednesday. Teva Pharmaceutical Industries has a 12 month low of $14.04 and a 12 month high of $25.96. The company has a market cap of $14.65 billion, a price-to-earnings ratio of 5.21, a price-to-earnings-growth ratio of 2.91 and a beta of 1.30. The company has a debt-to-equity ratio of 1.66, a current ratio of 0.96 and a quick ratio of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm had revenue of $4.30 billion during the quarter, compared to analysts’ expectations of $4.38 billion. During the same period in the previous year, the company earned $0.94 earnings per share. The firm’s quarterly revenue was down 15.2% on a year-over-year basis.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Hancock Whitney Corp increased its stake in shares of Teva Pharmaceutical Industries by 7.8% in the fourth quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock worth $186,000 after purchasing an additional 868 shares in the last quarter. Financial Counselors Inc. boosted its position in shares of Teva Pharmaceutical Industries by 0.7% during the fourth quarter. Financial Counselors Inc. now owns 124,805 shares of the company’s stock worth $1,924,000 after acquiring an additional 872 shares during the last quarter. Hartford Investment Management Co. boosted its position in shares of Teva Pharmaceutical Industries by 3.1% during the fourth quarter. Hartford Investment Management Co. now owns 29,581 shares of the company’s stock worth $456,000 after acquiring an additional 902 shares during the last quarter. Nwam LLC boosted its position in shares of Teva Pharmaceutical Industries by 3.1% during the fourth quarter. Nwam LLC now owns 30,083 shares of the company’s stock worth $464,000 after acquiring an additional 915 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its position in shares of Teva Pharmaceutical Industries by 61.2% during the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock worth $39,000 after acquiring an additional 945 shares during the last quarter. 67.01% of the stock is owned by hedge funds and other institutional investors.

In other news, VP Richard Daniell sold 2,098 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $16.88, for a total value of $35,414.24. Following the completion of the sale, the vice president now directly owns 2,098 shares of the company’s stock, valued at $35,414.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Notaristefani Carlo De sold 5,041 shares of the stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $17.88, for a total transaction of $90,133.08. Following the completion of the sale, the vice president now directly owns 17,162 shares of the company’s stock, valued at $306,856.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,691 shares of company stock valued at $283,458. Corporate insiders own 0.49% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: Why do company’s buyback their stock?

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.